Compare NBHC & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBHC | VRDN |
|---|---|---|
| Founded | 2009 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.2B |
| IPO Year | 2011 | 2014 |
| Metric | NBHC | VRDN |
|---|---|---|
| Price | $42.53 | $19.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 14 |
| Target Price | ★ $47.67 | $35.46 |
| AVG Volume (30 Days) | 398.7K | ★ 2.2M |
| Earning Date | 04-21-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.03% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.46 | N/A |
| Revenue | ★ $47,100,000.00 | $5,706,000.00 |
| Revenue This Year | $39.96 | $13.73 |
| Revenue Next Year | $7.14 | $279.00 |
| P/E Ratio | $94.20 | ★ N/A |
| Revenue Growth | ★ 2.86 | N/A |
| 52 Week Low | $35.06 | $13.18 |
| 52 Week High | $47.28 | $34.29 |
| Indicator | NBHC | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 42.02 | 61.76 |
| Support Level | $40.68 | $15.58 |
| Resistance Level | $43.14 | $20.00 |
| Average True Range (ATR) | 1.00 | 0.78 |
| MACD | -0.35 | -0.02 |
| Stochastic Oscillator | 15.34 | 84.22 |
National Bank Holdings Corp offers a full range of banking products and financial services to commercial, business, and consumer clients predominantly in Colorado, with a focus on personalized service through relationship managers and banking center associates. The company provides commercial and industrial loans, non-owner occupied commercial real estate loans, Small Business Administration loans as a Preferred Lender Provider, U.S. Department of Agriculture and Farm Service Agency loans, commercial deposit and treasury management products, business online and mobile banking, consumer and residential real estate loans, deposit services, and trust and wealth management services. Its services emphasize full-relationship banking, integrating lending, deposits, and cash management solutions.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.